Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Inovio Pharma (INO)

Inovio Pharma (INO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 267,587
  • Shares Outstanding, K 23,370
  • Annual Sales, $ 830 K
  • Annual Income, $ -135,120 K
  • 60-Month Beta 1.11
  • Price/Sales 323.02
  • Price/Cash Flow N/A
  • Price/Book 2.05
Trade INO with:

Options Overview Details

View History
  • Implied Volatility 106.83% ( -37.76%)
  • Historical Volatility 85.26%
  • IV Percentile 27%
  • IV Rank 5.51%
  • IV High 1,391.46% on 08/14/23
  • IV Low 31.96% on 06/26/23
  • Put/Call Vol Ratio 0.33
  • Today's Volume 320
  • Volume Avg (30-Day) 615
  • Put/Call OI Ratio 0.32
  • Today's Open Interest 18,484
  • Open Int (30-Day) 19,203

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -1.08
  • Number of Estimates 3
  • High Estimate -1.00
  • Low Estimate -1.17
  • Prior Year -1.92
  • Growth Rate Est. (year over year) +43.75%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.35 +38.80%
on 04/16/24
13.38 -13.38%
on 04/02/24
-1.53 (-11.66%)
since 04/01/24
3-Month
4.73 +145.03%
on 02/05/24
14.75 -21.41%
on 04/01/24
+6.28 (+118.27%)
since 02/01/24
52-Week
3.89 +198.10%
on 11/10/23
14.75 -21.41%
on 04/01/24
+2.45 (+26.80%)
since 05/01/23

Most Recent Stories

More News
Inovio Pharmaceuticals (INO) Q4 2023 Earnings Call Transcript

INO earnings call for the period ending December 31, 2023.

INO : 11.59 (+1.22%)
Inovio Pharmaceuticals (INO) Q3 2023 Earnings Call Transcript

INO earnings call for the period ending September 30, 2023.

INO : 11.59 (+1.22%)
Inovio: Q3 Earnings Snapshot

Inovio: Q3 Earnings Snapshot

INO : 11.59 (+1.22%)
INOVIO Announces U.S. FDA Breakthrough Therapy Designation Granted for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis

/PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...

INO : 11.59 (+1.22%)
Inovio Pharmaceuticals (INO) Q2 2023 Earnings Call Transcript

INO earnings call for the period ending June 30, 2023.

INO : 11.59 (+1.22%)
Inovio: Q2 Earnings Snapshot

Inovio: Q2 Earnings Snapshot

INO : 11.59 (+1.22%)
INOVIO Announces Second Quarter 2023 Financial Results and Provides Strategic Update

Preparing to initiate pivotal Phase 3 trial of INO-3107 in adult RRP patients in first quarter of 2024; INO-3107 received Orphan Drug Designation from European...

INO : 11.59 (+1.22%)
INOVIO Reports Inducement Grants Under Inducement Plan

/PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...

INO : 11.59 (+1.22%)
INOVIO to Report Second Quarter 2023 Financial Results on August 9, 2023

/PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...

INO : 11.59 (+1.22%)
INOVIO to Present at the 2023 Jefferies Healthcare Conference

/PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...

INO : 11.59 (+1.22%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Inovio Pharmaceuticals, Inc., formerly known as Inovio Biomedical Corporation, is engaged in the discovery, development, and delivery of a new generation of vaccines, called DNA vaccines, focused on cancers and infectious diseases. The Company's electroporation DNA delivery technology uses brief, controlled...

See More

Key Turning Points

3rd Resistance Point 13.29
2nd Resistance Point 12.84
1st Resistance Point 12.21
Last Price 11.59
1st Support Level 11.14
2nd Support Level 10.69
3rd Support Level 10.07

See More

52-Week High 14.75
Last Price 11.59
Fibonacci 61.8% 10.60
Fibonacci 50% 9.32
Fibonacci 38.2% 8.04
52-Week Low 3.89

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar